Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Boston Scientific (BSX – Research Report) and Humana (HUM – Research Report).
Boston Scientific (BSX)
In a report released yesterday, Anthony Petrone from Mizuho Securities maintained a Hold rating on Boston Scientific, with a price target of $52.00. The company’s shares closed last Thursday at $48.07.
According to TipRanks.com, Petrone is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific with a $53.64 average price target.
See today’s best-performing stocks on TipRanks >>
Humana (HUM)
In a report issued on February 1, Ann Hynes from Mizuho Securities maintained a Buy rating on Humana, with a price target of $615.00. The company’s shares closed last Thursday at $489.77.
According to TipRanks.com, Hynes is a 5-star analyst with an average return of
Currently, the analyst consensus on Humana is a Strong Buy with an average price target of $618.87, representing a 24.0% upside. In a report issued on January 17, Wells Fargo also maintained a Buy rating on the stock with a $610.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BSX:
- Boston Scientific price target raised to $52 from $50 at Stifel
- Piper remains bullish on Boston Scientific, says guidance likely conservative
- Boston Scientific sees FY23 adjusted EPS $1.86-$1.93, consensus $1.93
- Boston Scientific sees Q1 adjusted EPS 42c-44c, consensus 44c
- BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022
